Dr Martens shifts focus to sandals as profit plummets

Dr Martens shifts focus to sandals as profit plummets

Dr Martens has announced a new strategic focus after a bruising year which saw the brand nearly fall into the red. It will move away from a narrow focus on boots to a much broader approach targeting shoes, sandals and bags via a strategy called “Levers for Growth”. “Our ambition is to establish Dr. Martens as the world’s…


Dr Martens shifts focus to broader product range for growth.

Dr Martens has unveiled a new strategic direction following a challenging year that nearly placed the brand in financial difficulty. The company plans to broaden its focus from just boots to include shoes, sandals, and bags through a strategy named “Levers for Growth.” The aim is to establish Dr Martens as the world’s most desired premium footwear brand. The firm anticipates this new approach will yield a mid to high-teens EBIT margin in the medium term, resulting in a nearly 13 per cent rise in its share price in early trading.

Chief executive Ije Nwokorie emphasised the intention to encourage more consumers to purchase a wider array of products. The strategy involves shifting from a channel-first to a consumer-first mindset, tailoring distribution to each market by blending direct-to-consumer and business-to-business approaches to optimise brand reach and capital use.

However, there are concerns about the lack of heritage in these new product lines. Analyst Dan Lane from Robinhood noted that Dr Martens is known for its anti-establishment boots, and straying too far from this could harm the brand’s image. He compared the situation to Burberry’s return to its roots, suggesting that it remains to be seen whether Dr Martens will succeed with a broader product range or will need to refocus on its iconic offerings.

In 2024, Dr Martens reported a ten per cent decrease in revenue to £787.6m, aligning with expectations. Direct-to-consumer revenue, making up 64.8 per cent of earnings, fell by 4.2 per cent, while wholesale revenue dropped by 19.5 per cent. Adjusted earnings before interest and tax fell from £126.4m to £60.7m, and profit before tax decreased to £8.8m from £93m the previous year.

Despite these challenges, Dr Martens achieved its objectives for the year, with the US market returning to growth in the second half, cost savings, a stronger marketing presence, and an improved balance sheet. Nwokorie stated that the focus in FY25 was to stabilise the company and highlighted significant growth opportunities, noting that Dr Martens currently holds just 0.7 per cent of a £179bn market. He expressed confidence in the brand’s potential for sustainable, profitable growth, citing robust demand, strong operations, cashflow generation, and the expertise of its people.



  • OpenAI launches enterprise platform to win business customers

    OpenAI launches enterprise platform to win business customers

    OpenAI has launched a new enterprise platform aimed at business customers. The move signals a deeper push into corporate software, as the company looks to scale AI deployment inside large organisations and grow enterprise revenues.


  • SolarWinds unveils refreshed global partner programme

    SolarWinds unveils refreshed global partner programme

    SolarWinds has launched a revamped global partner programme for 2026. The initiative, announced at the company’s February Partner Summit, introduces enhanced benefits, enablement, and marketing investments aimed at accelerating partner-led growth.


  • Owl Labs launches enterprise-focused Meeting Owl 5 Pro

    Owl Labs launches enterprise-focused Meeting Owl 5 Pro

    Owl Labs has launched its Meeting Owl 5 Pro enterprise device. The new 360-degree video, audio, and collaboration system targets large organisations seeking flexible, secure hybrid meeting room deployments.